-
Mitochondrial inhibitors show preferential cytotoxicity to human pancreatic cancer PANC-1
cells under glucose-deprived conditions.
I. Momose, S. Ohba, D. Tatsuda, M. Kawada, T. Masuda, G. Tsujiuchi, T. Yamori, H. Esumi
and D. Ikeda.
Biochem Biophys Res Commun. 2010, 392, 460-466.
-
Rubratoxin A specifically and potently inhibits protein phosphatase 2A and suppresses
cancer metastasis.
S. Wada, I. Usami, Y. Umezawa, H. Inoue, S. Ohba, T. Someno, M. Kawada and D. Ikeda.
Cancer Sci. 2010, 101, 743-750.
-
Leucinostatin A inhibits prostate cancer growth through reduction of insulin-like growth
factor-I expression in prostate stromal cells.
M. Kawada, H. Inoue, S. Ohba, T. Masuda, I. Momose and D. Ikeda.
Int J Cancer. 2010, 126, 810-818.
-
Ceramidastin, a novel bacterial ceramidase inhibitor, produced by Penicillium sp.
Mer-f17067.
H. Inoue, T. Someno, T. Kato, H. Kumagai, M. Kawada and D. Ikeda.
J Antibiot. 2009, 62, 63-67.
-
Phthoxazolin A inhibits prostate cancer growth by modulating tumor-stromal cell
interactions.
M. Kawada, H. Inoue, I. Usami and D. Ikeda.
Cancer Sci. 2009, 100, 150-157.
-
Transforming growth factor-β1 modulates tumor-stromal cell interactions of prostate
cancer through insulin-like growth factor-I.
M. Kawada, H. Inoue, M. Arakawa and D. Ikeda.
Anticancer Res. 2008, 28, 721-730.
-
Highly tumorigenic human androgen receptor-positive prostate cancer cells overexpress
angiogenin.
M. Kawada, H. Inoue, M. Arakawa, K. Takamoto, T. Masuda and D. Ikeda.
Cancer Sci. 2007, 98, 350-356.
